[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:uveal-melanoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":178,"states":183},"Uveal Melanoma",27,23,[8,16,23,30,36,42,48,54,61,67,73,79,86,92,98,104,110,116,122,128,134,140,146,152,159,166,172],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06246149","Adjuvant Tebentafusp in High Risk Ocular Melanoma",[12],"Phase 3","RECRUITING","2026-08-26T02:17:07.954622Z","2026-07-05T03:45:20.245754Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06414590","Neoadjuvant Tebentafusp for Uveal Melanoma",[20],"Phase 2","2026-08-26T02:17:43.321968Z","2026-06-16T05:54:07.916679Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06626516","Tebentafusp-tebn With LDT in Metastatic UM",[27],"Phase 1\u002FPhase 2","2026-08-26T02:18:08.005333Z","2026-05-05T02:43:29.333515Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT07136181","Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma",[27],"2026-08-26T02:15:24.145250Z","2026-05-05T02:43:29.073997Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT06121180","Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma",[20],"2026-08-26T02:16:54.044282Z","2026-05-05T02:43:29.039725Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT06070012","Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma",[20],"2026-08-26T02:17:23.750999Z","2026-05-05T02:43:28.678056Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT06627244","Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma",[20],"2026-08-26T02:15:48.613507Z","2026-05-05T02:43:28.511438Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":59,"content_modified":60},"NCT06581406","A Randomized, Phase 2\u002F3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma",[58],"Phase 2\u002FPhase 3","2026-08-26T02:16:24.970704Z","2026-05-05T02:43:28.356896Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT06932757","Adjuvant Quisinostat in High-Risk Uveal Melanoma",[20],"2026-08-26T02:18:32.765187Z","2026-05-05T02:43:27.836810Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT07015190","Neoadjuvant Darovasertib in Primary Uveal Melanoma",[12],"2026-08-26T02:17:51.502023Z","2026-05-05T02:43:27.065288Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT07276386","Phase 2 Combination of Melphalan\u002FHDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma",[20],"2026-08-26T02:16:12.203827Z","2026-04-29T02:57:57.149508Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":84,"content_modified":85},"NCT05607095","A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma",[83],"Phase 1","2026-08-26T02:18:51.009190Z","2026-07-19T19:36:05.123927Z",{"nct_id":87,"title":88,"phases":89,"status":13,"updated_at":90,"content_modified":91},"NCT04219254","A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors",[27],"2026-08-26T02:17:18.747857Z","2026-05-05T02:43:27.627061Z",{"nct_id":93,"title":94,"phases":95,"status":13,"updated_at":96,"content_modified":97},"NCT03947385","Study of IDE196 in Patients With Solid Tumors Harboring GNAQ\u002F11 Mutations or PRKC Fusions",[27],"2026-08-26T02:17:05.997056Z","2026-05-05T02:43:26.921459Z",{"nct_id":99,"title":100,"phases":101,"status":13,"updated_at":102,"content_modified":103},"NCT06021626","A Study of CRD3874-SI in People With Solid Tumors",[83],"2026-08-26T02:16:32.589113Z","2026-07-05T05:32:16.744495Z",{"nct_id":105,"title":106,"phases":107,"status":13,"updated_at":108,"content_modified":109},"NCT05785754","DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors",[83],"2026-08-26T02:15:39.267524Z","2026-05-05T02:43:29.040176Z",{"nct_id":111,"title":112,"phases":113,"status":13,"updated_at":114,"content_modified":115},"NCT06961357","Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma",[27],"2026-08-26T02:15:04.877798Z","2026-05-05T02:43:28.848519Z",{"nct_id":117,"title":118,"phases":119,"status":13,"updated_at":120,"content_modified":121},"NCT06805825","A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and\u002For Metastatic Solid Tumors Known to Express c-Kit",[83],"2026-08-26T02:16:33.772093Z","2026-05-05T02:43:27.274696Z",{"nct_id":123,"title":124,"phases":125,"status":13,"updated_at":126,"content_modified":127},"NCT06022029","A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.",[83],"2026-08-26T02:19:07.104270Z","2026-05-05T02:43:26.751098Z",{"nct_id":129,"title":130,"phases":131,"status":13,"updated_at":132,"content_modified":133},"NCT05844982","Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy",[12],"2026-08-26T02:16:04.914942Z","2026-05-05T02:43:27.659965Z",{"nct_id":135,"title":136,"phases":137,"status":13,"updated_at":138,"content_modified":139},"NCT04792463","Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome",[],"2026-08-26T02:15:56.561131Z","2026-05-13T02:55:06.269987Z",{"nct_id":141,"title":142,"phases":143,"status":13,"updated_at":144,"content_modified":145},"NCT07364474","Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver",[],"2026-08-26T02:17:30.145302Z","2026-05-05T02:43:29.395365Z",{"nct_id":147,"title":148,"phases":149,"status":13,"updated_at":150,"content_modified":151},"NCT06940739","A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel",[27],"2026-08-26T02:16:39.977107Z","2026-05-05T02:43:27.628635Z",{"nct_id":153,"title":154,"phases":155,"status":156,"updated_at":157,"content_modified":158},"NCT07057349","CSB-321 Ph 1 in Immunotherapy for the Treatment of Cancer",[83],"NOT_YET_RECRUITING","2026-08-26T02:19:13.549512Z","2026-05-05T02:43:29.542850Z",{"nct_id":160,"title":161,"phases":162,"status":163,"updated_at":164,"content_modified":165},"NCT05524935","Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma",[20],"ACTIVE_NOT_RECRUITING","2026-08-03T03:33:53.839199Z","2026-05-05T02:43:27.800141Z",{"nct_id":167,"title":168,"phases":169,"status":163,"updated_at":170,"content_modified":171},"NCT03467516","Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma",[20],"2026-08-03T02:00:40.724107Z","2026-05-05T02:43:27.053928Z",{"nct_id":173,"title":174,"phases":175,"status":163,"updated_at":176,"content_modified":177},"NCT04130516","Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab",[27],"2026-08-03T02:56:50.780912Z","2026-05-05T02:43:26.771370Z",[179],{"biomarker":180,"count":181,"slug":182},"HLA Class I Histocompatibility Antigen, A-0201 Alpha Chain",6,"hla-class-i-histocompatibility-antigen-a-0201-alpha-chain",[184,188,192,196,200,203,206,209,213,216,220,224,227,231,234,237,240,243],{"state":185,"count":186,"slug":187},"Florida",11,"florida",{"state":189,"count":190,"slug":191},"Pennsylvania",10,"pennsylvania",{"state":193,"count":194,"slug":195},"New York",9,"new-york",{"state":197,"count":198,"slug":199},"California",8,"california",{"state":201,"count":198,"slug":202},"Colorado","colorado",{"state":204,"count":198,"slug":205},"Ohio","ohio",{"state":207,"count":198,"slug":208},"Texas","texas",{"state":210,"count":211,"slug":212},"Massachusetts",7,"massachusetts",{"state":214,"count":211,"slug":215},"Tennessee","tennessee",{"state":217,"count":218,"slug":219},"Minnesota",5,"minnesota",{"state":221,"count":222,"slug":223},"Arizona",4,"arizona",{"state":225,"count":222,"slug":226},"Michigan","michigan",{"state":228,"count":229,"slug":230},"Connecticut",3,"connecticut",{"state":232,"count":229,"slug":233},"Illinois","illinois",{"state":235,"count":229,"slug":236},"Iowa","iowa",{"state":238,"count":229,"slug":239},"North Carolina","north-carolina",{"state":241,"count":229,"slug":242},"Virginia","virginia",{"state":244,"count":229,"slug":245},"Wisconsin","wisconsin"]